haEmatology and oncology
ESTRO 38: Targeting
optimal care, together
On behalf of the ESTRO Scientific Advisory Group, it is our
honour and pleasure to invite you to ESTRO 38, the annual congress
of ESTRO, that will take place 26–30 April 2019 in Milan, Italy
Umberto Ricardi MD
Chair, ESTRO 38,
University of Turin, Italy
ESTRO 38 will offer to us all, as professionals of
oncology, the chance to share knowledge, practice
and advances in the field, within the ever warm
and dynamic environment of the ESTRO meetings.
‘Targeting optimal care, together’ will be the
theme of ESTRO 38 and through these few,
however impactful words, the Scientific and
Organising Committees would like to put
a spotlight on the multiprofessional and
multidisciplinary aspect of our specialty. The
theme also represents our strength: we are all
working towards a common goal for improved
patient outcomes, and this will be expressed
throughout the scientific programme:
• Targeting: the concept is inherent to the
radiation oncology specialty, and certainly well
in line with the modern concept of precision
medicine.
• Optimal care: the value and the cost for
radiotherapy are an inseparable part of the
equation for optimal treatment. Although the
clinical outcome of our patients is the priority
in our daily practice, this cannot happen without
common efforts to improve the access to
treatment for all cancer patients.
• Together: the radiation oncology community
is a mosaic of various stakeholders: medical and
scientific communities, industry, national societies
as well as oncology organisations, institutes,
patients and advocates. We all join forces.
Planned sessions
The interdisciplinary component of the scientific
programme will include sessions on the following
topics:
• Artificial Intelligence in radiation oncology:
role and potential
• Radio-immunotherapy
• Adaptive radiotherapy (ART) guided by early
response (adapting the adaptive!)
• Adaptive radiotherapy (ART): reactive or
proactive?
• MR machines and treatment adaptation
• Clinical trials for particle therapy: which ones
to run and how?
• The DNA damage response with radiotherapy
• Radiotherapy biomarkers: a confluence of
imaging, genetics and pathology
• Cardiac substructures and toxicity
• Predictive models of toxicity and big data,
big open issues
• The role of hypofractionation in current
radiotherapy and its impact in planning
5
HHE 2018 | hospitalhealthcare.com
radiotherapy services
• Palliation in radiotherapy – How much
is enough?
• Are adolescents and young adults a specific
patient population?
• Plan of the day. General gains of performing
• Re-irradiation for breast cancer
• Extreme hypofractionation in the treatment
of localised prostate cancer
• Radiotherapy in bladder cancer: standard of care
and future perspectives
• Which is the best technique for the delivery
of APBI?
• From discovery to cure
• Dose painting – what is the reality?
• Inflammatory environmental factors and
radiation response
• Functional imaging in radiotherapy: from
biology to guidance
• Role of ablative treatments in oligometastatic
disease.
With symposia, proffered papers sessions and
debates, ESTRO 38 will offer ample opportunities
to learn about cutting-edge research from leading
scientists.
A strong educational platform will also feature
worldwide experts who will give pre-meeting
courses, teaching lectures, contouring workshops
and multidisciplinary tumour boards during five
days.
The Young Scientists’ Track has now become
a not to be missed event within the congress
with a one-day programme tailored to the young
audience. Lectures, symposia and networking
opportunities are on the agenda.
ESTRO’s annual congresses feature the largest
exhibition in radiation oncology in Europe, with
an increasing number of exhibitors year after year.
Be there and get a chance to meet all the industry
leaders show-casing the latest developments in
the radiotherapy and oncology fields.
Finally, I’m proud to be part of a society that
places quality at the heart of all its scientific
moves. The state of the art science presented
by worldwide participants at the ESTRO annual
congresses impresses me each year. Today I’m
inviting you to take note of the abstract deadline:
submit your work by 22 October 2018 and be part
of this outstanding scientific programme.
We look forward to welcoming you in elegant
and majestic Milan, where we hope you will join
us to make ESTRO 38 a memorable event for the
radiation oncology community.